Lupa

Show document Help

A- | A+ | Print
Title:Adjuvant TNF-a therapy to electrochemotherapy with intravenous cisplatin in murine sarcoma exerts synergistic antitumor effectiveness
Authors:ID Čemažar, Maja (Author)
ID Todorović, Vesna (Author)
ID Ščančar, Janez (Author)
ID Lampreht Tratar, Urša (Author)
ID Savarin, Monika (Author)
ID Kamenšek, Urška (Author)
ID Kranjc Brezar, Simona (Author)
ID Cör, Andrej (Author)
ID Serša, Gregor (Author)
Files:URL http://www.dlib.si/details/URN:NBN:SI:doc-KBJJJ704
 
Language:English
Work type:Not categorized
Typology:1.01 - Original Scientific Article
Organization:FVZ - Faculty of Health Sciences
Abstract:Background. Electrochemotherapy is a tumour ablation modality, based on electroporation of the cell membrane, allowing non-permeant anticancer drugs to enter the cell, thus augmenting their cytotoxicity by orders of magnitude. In preclinical studies, bleomycin and cisplatin proved to be the most suitable for clinical use. Intravenous administration of cisplatin for electrochemotherapy is still not widely accepted in the clinics, presumably due to its lower antitumor effectiveness, but adjuvant therapy by immunomodulatory or vascular-targeting agents could provide a way for its potentiation. Hence, the aim of the present study was to explore the possibility of adjuvant tumour necrosis factor % (TNF-%) therapy to potentiate antitumor effectiveness of electrochemotherapy with intravenous cisplatin administration in murine sarcoma. Materials and methods. In vivo study was designed to evaluate the effect of TNF-% applied before or after the electrochemotherapy and to evaluate the effect of adjuvant TNF-% on electrochemotherapy with different cisplatin doses. Results. A synergistic interaction between TNF-% and electrochemotherapy was observed. Administration of TNF-% before the electrochemotherapy resulted in longer tumour growth delay and increased tumour curability, and was significantly more effective than TNF-% administration after the electrochemotherapy. Tumour analysis revealed increased platinum content in tumours, TNF-% induced blood vessel damage and increased tumour necrosis after combination of TNF-% and electrochemotherapy, indicating an anti-vascular action of TNF-%. In addition, immunomodulatory effect might have contributed to curability rate of the tumours. Conclusion. Adjuvant intratumoural TNF-% therapy synergistically contributes to electrochemotherapy with intravenous cisplatin administration. Due to its potentiation at all doses of cisplatin, the combined treatment is predicted to be effective also in tumours, where the drug concentration is suboptimal or in bigger tumours, where electrochemotherapy with intravenous cisplatin is not expected to be sufficiently effective.
Keywords:electrochemotherapy, TNF, adjuvant immunotherapy, cisplatin
Year of publishing:2015
Number of pages:str. 32-40, III
Numbering:Vol. 49, no. 1
PID:20.500.12556/RUP-7750 This link opens in a new window
ISSN:1318-2099
UDC:602.6/.7
DOI:10.1515/raon-2015-0005 This link opens in a new window
COBISS.SI-ID:1975163 This link opens in a new window
Publication date in RUP:08.08.2016
Views:6177
Downloads:136
Metadata:XML DC-XML DC-RDF
:
Copy citation
  
Average score:(0 votes)
Your score:Voting is allowed only for logged in users.
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Secondary language

Language:Slovenian
Keywords:elektrokemoterapija, tumorski nekrotizirajoči faktor, intravenska elektrokemoterapija, dopolnilna imunska terapija


Comments

Leave comment

You must log in to leave a comment.

Comments (0)
0 - 0 / 0
 
There are no comments!

Back
Logos of partners University of Maribor University of Ljubljana University of Primorska University of Nova Gorica